Table 3 SOGUG Guideline compliance according to treatment
Sunitinib 977 | Sorafenib 247 | Pazopanib 210 | Everolimus 166 | Temsirolimus 125 | Bevacizumab 24 | Total 1,858 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre 534 | Post 443 | Pre 157 | Post 90 | Pre 1 | Post 209 | Pre 130 | Post 145 | Pre 56 | Post 69 | Pre 14 | Post 10 | Pre 892 | Post 966 | |
Overall compliance, n cycles (%) | ||||||||||||||
Yes | 136 (25.5) | 123 (27.8) | 17 (10.8) | 2 (2.2)* | 0 (0.0) | 68 (32.5) | 42 (32.3) | 67 (46.2)* | 8 (14.3) | 17 (24.6) | 3 (21.4) | 0 (0.0) | 206 (23.1) | 277 (28.7)* |
No | 398 (75.5) | 320 (72.2) | 140 (89.2) | 88 (97.8) | 1 (100) | 141 (67.5) | 88 (67.7) | 78 (53.8) | 48 (85.7) | 52 (75.4) | 11 (78.6) | 10 (100) | 686 (76.9) | 689 (71.3) |
Guidelines compliance by adverse event, n cycles (%)a | ||||||||||||||
Hypertension | 173 (43.5) | 171 (53.4)* | 1 (0.7) | 0 (0.0) | 0 (0.0) | 69 (48.9) | – | – | – | – | 9 (81.8) | 9 (90.0) | 183 (33.3) | 249 (44.5)£ |
Cardiac toxicity | 113 (28.4) | 87 (27.2) | – | – | – | – | – | – | – | – | – | – | 113 (28.4) | 87 (27.2) |
Skin toxicity | 398 (100) | 320 (100) | 140 (100) | 88 (100) | – | – | – | – | 48 (100) | 52 (100)- | – | – | 586 (100) | 460 (100) |
Hypothyroidism | 172 (43.2) | 157 (49.1) | – | – | – | – | – | – | – | – | – | – | 172 (43.2) | 157 (49.1) |
Diarrhea | 274 (68.8) | 264 (82.5)£ | 124 (88.6) | 73 (83.0) | 1 (100) | 105 (74.5) | – | – | – | – | – | – | 399 (74.0) | 442 (80.5)* |
Hyperglycemia | – | – | – | – | – | – | 63 (71.6) | 53 (67.9) | 28 (58.3) | 39 (75.0) | – | – | 91 (66.9) | 92 (70.8) |
Dyslipemia | – | – | – | – | – | – | 22 (25.0) | 42 (53.8) £ | 12 (25.0) | 16 (30.8) | – | – | 34 (25.0) | 58 (44.6)# |
Pneumonitis | – | – | – | – | – | – | 53 (60.2) | 42 (53.8) | 31 (64.6) | 32 (61.5) | – | – | 84 (61.8) | 74 (56.9) |
Liver toxicity | – | – | – | – | 1 (100) | 37 (26.2) | – | – | – | – | – | – | 1 (100) | 37 (26.2) |
Proteinuria | – | – | – | – | – | – | – | – | – | – | 2 (18.2) | 0 (0.0) | 2 (18.2) | 0 (0.0) |